Trials
6 active
10 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “AND017 capsules administered orally with a starting dose of 10 mg TIW”In the company’s words, NCT07494409 on ClinicalTrials.gov
- Tested for
- Anemia Due to Chronic Kidney Disease (2 trials), β -Thalassemia, Myelodysplastic Syndromes, Chemotherapy Induced Anemia, Cancer-Related Anemia
- Main trialPhase 3
- “This is a phase III, randomized, open-label, active-controlled study to evaluate the safety and efficacy of AND017 in anemic patients with End-Stage-Kidney-Disease (ESKD)”In the company’s words, NCT07494409 on ClinicalTrials.gov
Other drugs for Anemia Due to Chronic Kidney Disease
- NTQ5082Nanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- MY008211AWuhan Createrna Science and Technology Co., Ltd · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- CrovalimabRoche · Phase 3
- DanicopanAlexion Pharmaceuticals, Inc. · Phase 3
- QLG1218Qilu Pharmaceutical · Phase 3
Coming up6
- DecPhase 2 trial completes · ClinicalTrials.gov
- DecPhase 2 trial completes · ClinicalTrials.gov
- 20 Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- 1 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- May 2028Phase 2 trial completes · ClinicalTrials.gov
Changes3
Last 90 days- 18 NovCompletion date moved: 2026-12-01 to 2027-03-01 · ClinicalTrials.gov NCT07487727
- 18 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT07494409
- 18 NovCompletion date moved: 2026-10-30 to 2027-02-20 · ClinicalTrials.gov NCT07494409
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 20 Feb 2027 | A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia | |
| Phase 3Recruiting | 1 Mar 2027 | A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) | |
| Phase 2Recruiting | Dec 2026 | A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia | |
| Phase 2Recruiting | Dec 2026 | A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome | |
| Phase 2Not yet recruiting | Dec 2027 | A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy | |
| Phase 2Not yet recruiting | May 2028 | A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy | |
| Phase 2Completed | 5 Jul 2023 | A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients | |
| Phase 2Completed | 29 Feb 2024 | A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis | |
| Phase 1Completed | 11 Feb 2019 | A Dose-escalation Study of AND017 in Healthy Subjects | |
| Phase 1Completed | 16 Aug 2020 | A Food-Effect Study of AND017 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026